Rate My Professor Roger Liang

In 2011, he accepted a lecturer position at the University of Newcastle to establish a drug delivery research group and progressed to Associate Professor in Pharmacy and Experimental Pharmacology. Previously, at the University of New South Wales' Centre for Advanced Macromolecular Design, he created a platform technology for efficient albendazole delivery in anti-cancer treatment. Liang's research focuses on advanced drug delivery and nanomedicine, integrating chemical and molecular engineering, materials science, chemistry, biotechnology, and medicine. He engineers novel biomaterials via self-assembly into nano-, micro-, and macro-structures for disease therapy and diagnosis. Research fields encompass nanomedicine (40%) and clinical pharmacology and therapeutics (60%). Key publications include "Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation" (Nature Nanotechnology, 2011), "Targeting respiratory virus-induced reactive oxygen species in airways diseases" (European Respiratory Review, 2025), "Engineering pH-sensitive dissolution of lipid-polymer nanoparticles by Eudragit integration impacts plasmid DNA (pDNA) transfection" (European Journal of Pharmaceutics and Biopharmaceutics, 2024), and "Design and Synthesis of Cabazitaxel Loaded Core-Shell Mesoporous Silica Nanoparticles with Different Morphologies for Prostate Cancer Therapy" (Small, 2024). Liang has supervised nine completed PhD theses and oversees three current ones, covering adrenal-targeted nano-biotechnology, airway epithelial cell-targeting nanoparticles, and more. His contributions have advanced understanding of nanoparticle toxicity and innovative therapeutic delivery systems for cancer, respiratory conditions, and reproductive health.